Recent clinical studies showed that methylation of MGMT is a useful predictor of the responsiveness of tumors to alkylating agents in gliomas [45, 46], and is associated with good survival in patients treated with multidrug regimens [47]. This evidence concerns the gene MGMT and central nervous system cancer.